Scalper1 News
Big-cap biotechs were moving in strong volume on the stock market today as Deutsche Bank added several of them to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst Robyn Karnauskas touted it as a short-term investment idea, saying the read-out of clinical-trial data from a new drug for Crohn’s disease could move the stock in October. The company Scalper1 News
Scalper1 News